Active and passive immunotherapy for neurodegenerative disorders.

Immunotherapeutic strategies to combat neurodegenerative disorders have galvanized the scientific community since the first dramatic successes in mouse models recreating aspects of Alzheimer disease (AD) were reported. However, initial human trials of active amyloid-beta (Abeta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. Nonetheless, some encouraging preliminary data were obtained, and rapid progress has been made toward developing alternative, possibly safer active and passive immunotherapeutic approaches for several neurodegenerative conditions. Many of these are currently in human trials for AD. Despite these advances, our understanding of the essential mechanisms underlying the effects seen in preclinical models and human subjects is still incomplete. Antibody-induced phagocytosis of pathological protein deposits, direct antibody-mediated disruption of aggregates, neutralization of toxic soluble proteins, a shift in equilibrium toward efflux of specific proteins from the brain, cell-mediated immune responses, and other mechanisms may all play roles depending on the specific immunotherapeutic scenario.

[1]  E. Jenner.  An Inquiry into the Causes and Effects of the Variolae Vaccinae A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox , 2010 .

[2]  H. Schätzl,et al.  Vaccination with prion peptide‐displaying papillomavirus‐like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells , 2007, The FEBS Journal.

[3]  H. Gendelman,et al.  Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS , 2007, Neurobiology of Disease.

[4]  A. Frey,et al.  Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies , 2007, Expert review of vaccines.

[5]  S. J. Martin,et al.  Active β-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of β-Amyloid , 2007, The Journal of Neuroscience.

[6]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[7]  J. Julien,et al.  Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis , 2007, Proceedings of the National Academy of Sciences.

[8]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[9]  R. Hepler,et al.  Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .

[10]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[11]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[12]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[13]  S. Paul,et al.  Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. , 2006, The Journal of clinical investigation.

[14]  J. Trojanowski,et al.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. , 2006, Annual review of pathology.

[15]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[16]  E. Sigurdsson,et al.  Mucosal vaccination delays or prevents prion infection via an oral route , 2005, Neuroscience.

[17]  D. Holtzman,et al.  IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor , 2005, The Journal of Neuroscience.

[18]  S. Greenberg,et al.  Treatment and prevention of primary intracerebral hemorrhage. , 2005, Seminars in neurology.

[19]  V. Devita,et al.  Herceptin: HERalding a new era in breast cancer care but at what cost? , 2005, Nature Clinical Practice Oncology.

[20]  K. Matsui,et al.  The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain , 2005, Neurobiology of Disease.

[21]  L. Sävendahl.  Hormonal Regulation of Growth Plate Cartilage , 2005, Hormone Research in Paediatrics.

[22]  E. Masliah,et al.  β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[23]  R. Black,et al.  Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies , 2005 .

[24]  H. Weiner,et al.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. , 2005, The Journal of clinical investigation.

[25]  D. Holtzman,et al.  Treatment with an Amyloid-β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[26]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[27]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[28]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[29]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[30]  W. Colledge.  Faculty Opinions recommendation of Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. , 2005 .

[31]  D. Holtzman,et al.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. , 2005, The Journal of clinical investigation.

[32]  W. H. Jordan,et al.  Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.

[33]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[34]  L. Jenkins,et al.  Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.

[35]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[36]  K. Jellinger.  Head injury and dementia , 2004, Current opinion in neurology.

[37]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[38]  H. Möller,et al.  Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[40]  H. Gendelman,et al.  Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[42]  M. Frosch,et al.  Clinical manifestations of cerebral amyloid angiopathy–related inflammation , 2004, Annals of neurology.

[43]  D. Wilcock,et al.  Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration , 2004, Neurobiology of Disease.

[44]  D. Holtzman,et al.  Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy , 2004 .

[45]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[46]  S. Scheff,et al.  Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.

[47]  Gregory A. Hickey,et al.  Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations , 2003, The Journal of Neuroscience.

[48]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[49]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[50]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[51]  D. Diamond,et al.  Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice , 2003 .

[52]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[53]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.

[54]  E. Yoles,et al.  Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[56]  J. Collinge,et al.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.

[57]  R. Motter,et al.  Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Staufenbiel,et al.  Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy , 2002, Science.

[59]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[60]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[61]  H. Möller,et al.  Progressive loss of cardiac sympathetic innervation in Parkinson's disease , 2002, Annals of neurology.

[62]  R. Nitsch,et al.  Passive Immunization against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer's Disease-causing Mutation* , 2002, The Journal of Biological Chemistry.

[63]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[64]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[65]  F. Heppner,et al.  Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.

[66]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[67]  S. Younkin,et al.  Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition , 2001, Neurobiology of Aging.

[68]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[70]  E. Masliah,et al.  Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease , 2001, Neurology.

[71]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[72]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[73]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[74]  A. Plückthun,et al.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. , 2000, Journal of molecular biology.

[75]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[76]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[77]  J. Trojanowski,et al.  Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. , 1998, The American journal of pathology.

[78]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[79]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[80]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[81]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[82]  B. Solomon,et al.  Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[84]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[85]  S. J. Martin,et al.  Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  John Q Trojanowski,et al.  Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. , 2006, Journal of Alzheimer's disease : JAD.

[87]  I. Ferrer,et al.  Amyloid- (cid:1) Peptide Remnants in AN-1792-Immunized Alzheimer’s Disease Patients A Biochemical Analysis , 2006 .

[88]  W. Klein,et al.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.

[89]  J. Trojanowski,et al.  Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. , 2006, The Journal of biological chemistry.

[90]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[91]  R. Hepler,et al.  Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.

[92]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[93]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[94]  R. Black,et al.  Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. , 2005, Annals of neurology.

[95]  E. Masliah,et al.  Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[96]  K. Matsui,et al.  The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. , 2005, Neurobiology of disease.

[97]  W. K. Cullen,et al.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.

[98]  D. Holtzman,et al.  Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[99]  D. Wilcock,et al.  Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. , 2004, Neurobiology of disease.

[100]  D. Holtzman,et al.  Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. , 2004, Journal of molecular biology.

[101]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[102]  D. Dickson,et al.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[103]  D. Wilcock,et al.  Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[104]  M. Staufenbiel,et al.  Cerebral hemorrhage after passive anti-Abeta immunotherapy. , 2002, Science.

[105]  B. Solomon,et al.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.